Arrhythmias & electrophysiologyCohort study
Temperature-guided high and very high-power short duration ablation for atrial fibrillation treatment: the peQasus multicentre study
- Prospective multicentre observational study
- 15 centres, 9 European countries
Authors' conclusion
In this large multicentre study, temperature-controlled HPSD and vHPSD ablation via a novel ablation catheter provides safe and effective PVI with a relatively short procedure duration.
Study context
- Population
- AF patients undergoing pulmonary vein isolation (PVI) with the QDOT Micro catheter
- Participants
- 1,023 patients · 15 centres
- Exposure
- vHPSD-only vs hybrid temperature-controlled ablation
- vHPSDn = 699
- hybridn = 324
- Outcome
- Safety, efficacy and freedom from atrial tachyarrhythmias
- Follow-up
- 12 months
Main finding
As reported in the abstract
12-month arrhythmia-recurrence-free survival
P = 0.241
- Overall arrhythmia-recurrence-free survival
- 77.1%
Observational data: associations, not effects.
Further findings
Procedure duration
P < 0.001
First-pass isolation of all PVs
P = 0.187
- Procedure duration — Overall mean procedure duration
- 98.4 ± 37.4 min
- First-pass isolation of all PVs — Overall
- 64%
Safety
Severe adverse events
P = 0.746
- Severe adverse events — Overall
- 1.7%
Original publication
Temperature-guided high and very high-power short duration ablation for atrial fibrillation treatment: the peQasus multicentre study. Europace. Published 7 November 2024. doi:10.1093/europace/euae284
Summarised from the published abstract; every number is checked against it